Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01532791 · ClinicalTrials.gov registry record

Natural History Study - Mitochondrial Disease

A clinical trial of MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier, sponsored by Columbia University.

Recruiting
Registry status
300
Enrollment target
1
Study location

NCT01532791 is a study of MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier that is actively recruiting participants, run by Columbia University. The registered enrollment target is 300 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01532791, a study of MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier, is actively recruiting participants, sponsored by Columbia University.

RECRUITING
Registry status
300 participants
Enrollment target
1
Study location

Study Summary

Carriers of the m.3242A\>G mutation often have clinical symptoms which can include migraines, seizures, strokes, hearing loss, balance issues, gastrointestinal issues, and many other symptoms. The investigators would like to learn more about these disorders and have designed a "Natural History Study" to monitor these conditions over time so that physicians and scientists can not only understand the problems that patients have, but work on developing treatments. The focus of the current work is to evaluate known mutation carriers of the m.3243A\>G (mitochondrial DNA) and their maternal relatives (carrier status not a requirement for participation). Paternal relatives will serve as controls. This study involves no treatment.

Study Locations (1)

New York

  • Columbia University - New York

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2004-07
Est. Completion 2026-07

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT01532791

The ClinicalTrials.gov registry entry for NCT01532791 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier appearing as the primary indexed condition, and to 0 interventions.

NCT01532791 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01532791 about?

NCT01532791 is a clinical study titled "Natural History Study - Mitochondrial Disease". Carriers of the m.3242A\>G mutation often have clinical symptoms which can include migraines, seizures, strokes, hearing loss, balance issues, gastrointestinal issues, and many other symptoms. The investigators would like to learn more about these disorders and have designed a "Natural History Study...

What is the current status of trial NCT01532791?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2004-07. Estimated completion is 2026-07.

What conditions does trial NCT01532791 study?

This clinical trial studies the following conditions: MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier.

Who is sponsoring clinical trial NCT01532791?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01532791 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.